Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2022-05-18 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PTX 7 pages 28.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited dated May 19, 2022, regarding the quotation of securities issued due to options being exercised or convertible securities being converted. It details the number of securities to be quoted, issue dates, and the nature of the securities (ordinary fully paid shares). The document references ASX Listing Rules Appendix 2A and includes specifics about the securities issued, but it does not contain financial statements, management discussion, or detailed financial results. It is clearly an announcement about a capital change related to securities issuance and quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is 7490 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or other types of filings.
2022-05-18 English
PTX-200 AML expansion after another complete response 4 pages 902.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of a clinical study cohort for a drug candidate (PTX-200) in acute myeloid leukemia (AML). It provides detailed information about patient responses, dose levels, and study plans. There are no financial statements, regulatory filings, or formal report structures such as annual or interim reports. The content focuses on clinical trial progress and company updates rather than financial results or governance. It is not a transcript, audit, or capital update. It is a company announcement about clinical trial progress and expansion, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-05-08 English
PTX-200 AML expansion after another complete response 5 pages 1.2MB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement re-released as price sensitive, dated 9 May 2022, regarding clinical trial updates for Prescient Therapeutics Limited. It discusses expansion of a clinical study cohort, patient responses, and drug development progress. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about clinical trial progress and company updates, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under a general regulatory announcement category for corporate news and clinical updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-05-08 English
Prescient to Present at AVID 2022 Meeting 22 pages 3.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Prescient Therapeutics Limited at the AVID 2022 Meeting, focusing on their OmniCAR platform and related scientific and clinical progress. It includes technical descriptions, forward-looking statements, risk factors, and scientific data. The content is consistent with an investor or scientific presentation rather than a formal regulatory filing, earnings release, or annual report. The document is lengthy (15,000 characters) and contains substantive information, not just an announcement or a brief summary. Therefore, it fits best as an Investor Presentation (IP).
2022-05-02 English
March 2022 Quarterly Update and Appendix 4C 9 pages 723.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'March 2022 Quarterly Update and Appendix 4C' and contains detailed financial and operational highlights for the quarter ended 31 March 2022. It includes cash flow statements, cash position, clinical trial progress, and other operational updates. The presence of Appendix 4C, which is a quarterly cash flow report required by the Australian Securities Exchange (ASX), confirms this is a quarterly financial report. The document is comprehensive, with substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q3 2022
2022-04-28 English
Notification of cessation of securities - PTX 5 pages 25.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Prescient Therapeutics Limited regarding the cessation of certain securities (options) due to lapse of conditional rights. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There are no financial statements, management discussion, or detailed financial data. The document is a regulatory announcement about changes in the company's issued capital, specifically about securities that have ceased. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation or lapse of securities.
2022-04-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.